ImmunoMet Therapeutics Promotes Benjamin Cowen to CEO

Benjamin Cowen, chief operating officer of ImmunoMet Therapeutics, is taking on a new role as CEO of the Houston-based drug developer. Founder and former CEO Sung-Wuk Kim will continue to serve as chairman of the company’s board of directors. Before joining ImmunoMet, Cowen was vice president of corporate development at Milestone Pharmaceuticals. ImmunoMet’s lead drug candidate, IM156, is being evaluated for potential use treating various cancers. The compound is currently in a Phase 1 study.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan